tenidap

Tenidap is a synthetic small molecule classified as a non-steroidal anti-inflammatory drug (NSAID) with unique cytokine-modulating and disease-modifying properties. It acts primarily as a cyclooxygenase (COX) inhibitor, showing greater selectivity for COX‑1 over COX‑2, and also exhibits weak inhibition of 5-lipoxygenase (5‑LOX). In addition to its effects on prostaglandin synthesis, tenidap inhibits the production of pro-inflammatory cytokines such as interleukin‑1 (IL‑1), interleukin‑6 (IL‑6), and tumor necrosis factor alpha (TNF-alpha), contributing to its anti-rheumatic activity. Developed by Pfizer for the treatment of rheumatoid arthritis, tenidap demonstrated both symptom-modifying and potential disease-modifying effects in clinical studies. However, development was discontinued after regulatory authorities rejected marketing approval due to concerns about liver and kidney toxicity linked to reactive metabolites[2][5][6][8].

Brand names

EnableKenidaReumatenTenedac

Other names

TenidapumTenidapum [INN-Latin]TENIDAP [USAN:INN:BAN](Z)-5-Chloro-3-(alpha-hydroxy-2-thienylidene)-2-oxo-1-indolinecarboxamide